1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Concord Drugs Ltd

Concord Drugs Ltd

BBSE:CONCORD
69.00
INR
+2.23
(+3.34%)
1.71EPS
45.01P/E
1.01BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
47.1
55.25
69.97
79.36
65.88
61.15
58.71
58.73
67.43
55.91
44.92
45.24
70.63
71.69
Basic EPS, GAAP
0.47
0.96
2.41
0.22
0.41
0.52
0.38
3.75
1.82
1.06
0.47
0.34
0.95
1.71
Free Cash Flow per Basic Share
- -
0.89
3.39
0.91
8.75
1.52
2.84
- -
0.89
1.79
0.79
3.72
-6.07
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
18.38
20.8
26.22
24.58
29.45
26.86
30.61
32.44
34.03
33.82
34.11
36.82
- -
Tangible Book Value per Share
- -
18.38
20.8
26.22
24.58
29.45
26.86
30.61
32.44
34.03
33.82
34.11
36.82
- -
Basic Weighted Avg Shares
7
7
7
7
8
8
9
9
9
9
10
10
11
12
Sales/Revenue/Turnover
340
400
507
575
518
481
513
514
590
521
449
452
787
861
Operating Margin (%)
6.51
9.41
11.02
5.19
4.29
5.18
3.66
3.89
15.54
5.84
5.65
6.13
4.04
5.2
Depreciation Expense
11
36
29
26
24
17
15
14
18
16
16
14
14
13
Net Income, GAAP
3
7
17
2
3
4
3
33
16
10
5
3
11
21
Effective Tax Rate (%)
20.93
33.63
41
75.35
49.25
7.44
28.08
23.54
29.08
21.09
24.9
51.37
28.39
28.28
Profit Margin (%)
1
1.74
3.45
0.28
0.63
0.85
0.64
6.39
2.7
1.89
1.05
0.74
1.34
2.38
Working Capital
- -
75
22
9
113
137
146
198
182
218
165
156
322
- -
LT Debt
- -
126
122
62
34
7
9
38
17
19
6
23
18
- -
Total Equity
- -
133
151
190
193
232
235
268
284
317
338
341
485
- -
Return on Invested Capital (%)
- -
- -
4.87
0.44
3.65
5.41
4.11
11.84
6.63
5.05
3.79
2.57
3.89
- -
Return on Capital (%)
- -
- -
9.3
2.18
3.65
5.65
4.14
11.81
6.59
5.03
3.75
2.49
3.84
- -
Return on Common Equity (%)
- -
- -
12.32
0.94
1.69
1.92
1.41
13.06
5.78
3.28
1.44
0.99
2.55
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
127
- -
LT Borrowings
- -
18
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
13
13
Market Capitalization
1,118
925
1,008

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
533
- -
Cash, Cash Equivalents & STI
- -
8
- -
Accounts Receivable, Net
- -
244
- -
Inventories
- -
255
- -
Total Current Liabilities
- -
211
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
127
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.05%
13.5%
42.21%
Free Cash Flow
477,985.73%
955,812.56%
-281.79%
Net Income, GAAP
96.15%
8.66%
213.8%
Sales/Revenue/Turnover
6.73%
12.83%
74.02%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
117
124
108
104
452
2026
136
103
170
379
787
2027
209
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.03
0.04
0.23
0.04
0.34
2026
0.12
0.19
0.16
0.47
0.95
2027
0.85
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Seelam Nagi Reddy
Full Time Employees
185
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Survey No. 249 Hyderabad TS India 501511
IPO Date
Feb 13, 2015
Website
concorddrugs.in
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Concord Drugs Limited (CONCORD.BO), a public limited company founded in 1995 and headquartered in Hyderabad, India, manufactures and sells pharmaceutical formulations, specializing in finished dosage forms and contract manufacturing services through WHO-GMP and cGMP-certified facilities located in Hyderabad, Telangana, and Roorkee, Uttarakhand; its core products encompass ready-to-fill pellets and multiple unit pellet systems (MUPS) with sustained release, modified release, enteric, delayed, and immediate release technologies; tissue bio-adhesives; small volume parenteral injectables; oral solid dosages including tablets and capsules; liquid orals such as syrups and suspensions; dry syrup powders; and additional offerings like hand sanitizers, serving domestic markets and select international registrations with emphasis on generics, branded formulations, and innovative drug delivery for prescription and over-the-counter applications. The company operates primarily in the Indian pharmaceutical sector, providing end-to-end solutions from research and development to commercial contract manufacturing for partners requiring high-quality, regulatory-compliant products. In recent developments, Concord Drugs approved the acquisition of up to 100% stake in Proton Remedies Private Limited in September 2022 for INR 14.2 million to expand its portfolio and capabilities; in November 2025, it closed a preferential funding round raising INR 133.6 million through equity shares and convertible warrants issued to promoters and investors at INR 36.30 per unit, bolstering financial resources amid quarterly net sales of INR 10.07 crore for September 2025; ongoing expansions include a dry syrup section started in 2021 and oral solid dosage production initiated in 2018.